Drug Treatment and Cost of Cardiovascular Disease in Australia
Zanfina Ademi, Danny Liew, Derek Chew, Greg Conner, Louise Shiel, Mark Nelson, Ash Soman, Gabriel Steg, Deepak L Bhatt, Christopher Reid
Cardiovascular Therapeutics | WILEY-HINDAWI | Published : 2009
Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prevention and secondary prevention in the community. We aim to understand annual expenditure on cardiovascular medicines according to the level and extent of cardiovascular disease, using participants enrolled in the Reduction of Atherothrombosis for Continued Health (REACH) registry. 2873 participants were recruited into the REACH registry through 273 Australian general practices. Cardiovascular medicines review was undertaken at baseline. Average weighted c..View full abstract
Awarded by Australian Research Council
The REACH registry is sponsored by Sanofi-Aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan). The REACH registry is endorsed by the World Heart Federation. A complete list of REACH investigators is accessible online at http://www.reachregistry.org. In addition, this work is supported in part by the Australian Research Council Linkage Project LP0775329. Support of this PhD work is provided by Monash University.